SCHEMBL1455574

SCHEMBL1455574

O=C(NCc1ccccc1)c1ccc(Sc2ccc(O)cc2)c(Nc2ncnc3ncccc23)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.51
BLM P54132 2/20 0.51
MAPK14 Q16539 1/20 0.46
PIM1 P11309 1/20 0.45
AKT2 P31751 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
ATM Q13315 1/20 0.42
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
HPGDS O60760 1/20 0.40
MAPK1 P28482 2/20 0.39
ROCK2 O75116 1/20 0.39
RPS6KA5 O75582 1/20 0.39
MAP4K4 O95819 1/20 0.39
PRKCG P05129 1/20 0.39
PRKACA P17612 1/20 0.39
RPS6KB1 P23443 1/20 0.39
AKT1 P31749 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1454915 0.93 PIM1 (0.45) TP53BLMMAPK14PIM1AKT2
SCHEMBL1455333 0.89 PIM1 (0.55) TP53BLMMAPK14PIM1AKT2
SCHEMBL1454529 0.88 PIM1 (0.60) TP53BLMMAPK14PIM1AKT2
SCHEMBL1454720 0.88 PIM1 (0.44) TP53BLMMAPK14PIM1AKT2
SCHEMBL1455210 0.84 PIM1 (0.43) MAPK14PIM1AKT2SMN1; SMN2KDM4E
SCHEMBL810273 0.82 PIM1 (0.60) TP53PIM1AKT2LMNASMN1; SMN2
SCHEMBL1455526 0.82 PIM1 (0.51) PIM1AKT2HTT
SCHEMBL1454780 0.82 PIM1 (0.45) TP53PIM1AKT2
SCHEMBL1455179 0.82 KCNQ3 (0.45) TP53BLMPIM1AKT2RXFP1
SCHEMBL1454182 0.81 NPC1 (0.42) MAPK14PIM1AKT2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979348-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-01-18 EP disclosed
US-7910595-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-22 US disclosed
EP-1979348-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232627-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076034-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232627-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 TP53 465/4885BLM 1449/4885MAPK14 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.